Innoviva, Inc. Files 8-K on Financials
Ticker: INVA · Form: 8-K · Filed: May 7, 2025 · CIK: 1080014
| Field | Detail |
|---|---|
| Company | Innoviva, INC. (INVA) |
| Form Type | 8-K |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: INVA
TL;DR
INVA filed an 8-K today covering financials. Check it out.
AI Summary
Innoviva, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 1350 Old Bayshore Highway, Suite 400, Burlingame, California.
Why It Matters
This 8-K filing provides investors with crucial updates on Innoviva's financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not indicate any unusual risks.
Key Players & Entities
- Innoviva, Inc. (company) — Registrant
- May 7, 2025 (date) — Date of earliest event reported
- 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010 (address) — Principal executive offices
- 650-238-9600 (phone_number) — Business phone number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on May 7, 2025.
What is Innoviva, Inc.'s primary business classification?
Innoviva, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Innoviva, Inc.'s principal executive offices located?
The principal executive offices are located at 1350 Old Bayshore Highway, Suite 400, Burlingame, California 94010.
What is the Commission File Number for Innoviva, Inc.?
The Commission File Number for Innoviva, Inc. is 000-30319.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 7, 2025 regarding Innoviva, Inc. (INVA).